166 related articles for article (PubMed ID: 23305737)
1. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer.
Schmidt K; Zilio S; Schmollinger JC; Bronte V; Blankenstein T; Willimsky G
Blood; 2013 Mar; 121(10):1740-8. PubMed ID: 23305737
[TBL] [Abstract][Full Text] [Related]
2. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.
Willimsky G; Schmidt K; Loddenkemper C; Gellermann J; Blankenstein T
J Clin Invest; 2013 Mar; 123(3):1032-43. PubMed ID: 23454765
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance.
Buschow C; Charo J; Anders K; Loddenkemper C; Jukica A; Alsamah W; Perez C; Willimsky G; Blankenstein T
J Immunol; 2010 Mar; 184(6):2930-8. PubMed ID: 20142365
[TBL] [Abstract][Full Text] [Related]
4. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
[TBL] [Abstract][Full Text] [Related]
5. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma.
Stahl S; Sacher T; Bechtold A; Protzer U; Ganss R; Hämmerling GJ; Arnold B; Garbi N
Immunol Lett; 2009 Mar; 123(1):31-7. PubMed ID: 19428549
[TBL] [Abstract][Full Text] [Related]
6. The immune response to sporadic colorectal cancer in a novel mouse model.
Czéh M; Loddenkemper C; Shalapour S; Schön C; Robine S; Goldscheid E; Stein H; Schüler T; Willimsky G; Blankenstein T
Oncogene; 2010 Dec; 29(50):6591-602. PubMed ID: 20818425
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
[TBL] [Abstract][Full Text] [Related]
8. Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
Chen EP; Markosyan N; Connolly E; Lawson JA; Li X; Grant GR; Grosser T; FitzGerald GA; Smyth EM
Carcinogenesis; 2014 Aug; 35(8):1788-97. PubMed ID: 24590894
[TBL] [Abstract][Full Text] [Related]
9. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
Kusmartsev S; Nefedova Y; Yoder D; Gabrilovich DI
J Immunol; 2004 Jan; 172(2):989-99. PubMed ID: 14707072
[TBL] [Abstract][Full Text] [Related]
11. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen.
Schell TD; Tevethia SS
J Immunol; 2001 Dec; 167(12):6947-56. PubMed ID: 11739514
[TBL] [Abstract][Full Text] [Related]
12. Analysis of splenic Gr-1int immature myeloid cells in tumor-bearing mice.
Yamamoto Y; Ishigaki H; Ishida H; Itoh Y; Noda Y; Ogasawara K
Microbiol Immunol; 2008 Jan; 52(1):47-53. PubMed ID: 18352913
[TBL] [Abstract][Full Text] [Related]
13. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
[TBL] [Abstract][Full Text] [Related]
14. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
[TBL] [Abstract][Full Text] [Related]
15. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
17. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
18. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells.
Narita Y; Wakita D; Ohkur T; Chamoto K; Nishimura T
Biomed Res; 2009 Feb; 30(1):7-15. PubMed ID: 19265258
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor.
Ge L; Zhang JG; Samathanam CA; Delgado C; Tarbiyat-Boldaji M; Dan Q; Hoa N; Nguyen TV; Alipanah R; Pham JT; Sanchez R; Wepsic HT; Morgan TR; Jadus MR
Cell Immunol; 2009; 259(2):117-27. PubMed ID: 19615673
[TBL] [Abstract][Full Text] [Related]
20. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T.
Burga RA; Thorn M; Point GR; Guha P; Nguyen CT; Licata LA; DeMatteo RP; Ayala A; Joseph Espat N; Junghans RP; Katz SC
Cancer Immunol Immunother; 2015 Jul; 64(7):817-29. PubMed ID: 25850344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
